This inventor holds 1 USPTO granted patent and 1 published patent application, plus 1 CIPO patent and 1 EPO patent. Top assignee: Beta Cat Pharmaceuticals, Inc.. Active years: 2016.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2016
Title: The Innovations of Stephen Horrigan
Introduction
Stephen Horrigan is an accomplished inventor based in Gaithersburg, MD (US). He has made significant contributions to the field of medical research, particularly in the treatment of diseases related to transducin β-like protein 1 (TBL1) activity. His work has implications for conditions such as myeloproliferative neoplasia and chronic myeloid leukemia.
Latest Patents
Stephen Horrigan holds a patent for "Methods for treatment of diseases and disorders related to transducin β-like protein 1 (TBL1) activity, including myeloproliferative neoplasia, chronic myeloid leukemia, and acute myeloid leukemia." This patent highlights his innovative approach to addressing complex medical challenges.
Career Highlights
Horrigan is currently associated with Beta Cat Pharmaceuticals, Inc., where he continues to advance his research and development efforts. His work at the company focuses on creating effective treatments for serious health conditions, showcasing his dedication to improving patient outcomes.
Collaborations
Stephen collaborates with notable professionals in his field, including Kapil N Bhalla. Their combined expertise contributes to the innovative projects at Beta Cat Pharmaceuticals, Inc.
Conclusion
Stephen Horrigan's contributions to medical research and his innovative patent demonstrate his commitment to advancing healthcare solutions. His work continues to inspire and pave the way for future developments in the treatment of serious diseases.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile